Regeneron Pharmaceuticals, Inc. (REGN) Price Target Analysis
Updated Jul 2, 2026
Analyst Rating: Buy
Based on 48 analysts23.6% Below Target
REGN trades 23.6% below Wall Street's consensus target of $836.00.
Current Price$676.23
Average Target$836.00
Target
Current
Low$641.00
Median$857.50
High$995.00
Analyst Target Range
Forward P/E14.6x
(Value)
PEG Ratio2.30
(Pricey)
Implied Growth+13.1%
(Moderate)
Analyst Spread42.3%
(Moderate)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes REGN achieves its forward estimates and maintains a stable P/E multiple of 14.6x. This scenario reflects the blended consensus of 48 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
REGN Price Target Analysis
Updated July 8, 2026As of July 8, 2026, Regeneron Pharmaceuticals, Inc. (REGN) has a Wall Street consensus price target of $836.00, based on estimates from 48 covering analysts. With the stock currently trading at $676.23, this represents a potential upside of +23.6%. The company has a market capitalization of $70.26B.
Analyst price targets range from a low of $641.00 to a high of $995.00, representing a 42% spread in expectations. The median target of $857.50 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 32 analysts rating the stock as a Buy or Strong Buy,16 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, REGN trades at a trailing P/E of 16.3x and forward P/E of 14.6x. The forward PEG ratio of 2.30 reflects a premium valuation. Analysts expect EPS to grow +13.1% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $812.16, with bear and bull scenarios of $511.66 and $1070.10 respectively. Model confidence stands at 57/100, reflecting moderate uncertainty in projections.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+8.6%
Industry Consensus
Avg Forward P/E
18.9x
(Fair)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 BIIBBiogen Inc. | $30.4B | $205.70 | $218.32 | +6.1% | Buy | 14.2x | 48 |
 VRTXVertex Pharmaceuticals Incorporated | $132.8B | $522.25 | $556.00 | +6.5% | Buy | 27.1x | 56 |
 INCYIncyte Corporation | $23.6B | $118.05 | $108.92 | -7.7% | Buy | 15.4x | 44 |
 BMRNBioMarin Pharmaceutical Inc. | $11.6B | $60.35 | $89.21 | +47.8% | Buy | 12.2x | 41 |
 ABBVAbbVie Inc. | $449.9B | $254.65 | $258.00 | +1.3% | Buy | 17.9x | 41 |
 LLYEli Lilly and Company | $1.2T | $1235.56 | $1269.94 | +2.8% | Buy | 33.7x | 45 |
 AMGNAmgen Inc. | $198.7B | $368.10 | $352.50 | -4.2% | Buy | 16.4x | 38 |
 GILDGilead Sciences, Inc. | $169.3B | $136.36 | $161.81 | +18.7% | Buy | — | 58 |
 MRKMerck & Co., Inc. | $318.3B | $128.86 | $133.77 | +3.8% | Buy | 25.1x | 37 |
 PFEPfizer Inc. | $136.9B | $24.07 | $26.75 | +11.1% | Hold | 8.1x | 39 |
REGN — Frequently Asked Questions
Quick answers to the most common questions about buying REGN stock.
What is the REGN stock price target for 2026?
The consensus Wall Street price target for REGN is $836, representing 23.6% upside from the current price of $676.23. With 48 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is REGN a buy, sell, or hold?
REGN has a consensus rating of "Buy" based on 48 Wall Street analysts. The rating breakdown is predominantly bullish, with 32 Buy/Strong Buy ratings. The consensus 12-month price target of $836 implies 23.6% upside from current levels.
Is REGN stock overvalued or undervalued?
With a forward P/E of 14.5553x, REGN trades at a relatively low valuation. The consensus target of $836 implies 23.6% appreciation, suggesting meaningful undervaluation.
How high can REGN stock go?
The most bullish Wall Street analyst has a price target of $995 for REGN, while the most conservative target is $641. The consensus of $836 represents the median expectation. Our quantitative valuation model projects a bull case target of $1070 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
How many analysts cover REGN stock?
REGN is heavily covered by Wall Street, with 48 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 32 have Buy ratings, 16 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the REGN stock forecast?
The 12-month REGN stock forecast based on 48 Wall Street analysts shows a consensus price target of $836, with estimates ranging from $641 (bear case) to $995 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $812, with bear/bull scenarios of $512/$1070.
What is REGN's fair value based on fundamentals?
Our quantitative valuation model calculates REGN's fair value at $812 (base case), with a bear case of $512 and bull case of $1070. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 57/100.
What is REGN's forward P/E ratio?
REGN trades at a forward P/E ratio of 14.6x based on next-twelve-months earnings estimates compared to a trailing P/E of 16.3x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy REGN stock?
Wall Street analysts are very optimistic on REGN, with a "Buy" consensus rating and $836 price target (23.6% upside). 32 of 48 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do REGN price targets vary so much?
REGN analyst price targets range from $641 to $995, a 42% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $836 consensus represents the middle ground. Our model's $512-$1070 range provides an independent fundamental perspective.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare